Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dotting out AML by targeting fibrillarin
    Editorial

    Luo, H.; Kharas, M. G.
    Cancer Research (2024)

    Fulltext@MSK | Save
  • Engineering immune-evasive allogeneic cellular immunotherapies
    Review

    Martin, K. E.; Hammer, Q.; Perica, K.; Sadelain, M.; Malmberg, K. J.
    Nature Reviews Immunology (2024)

    Fulltext@MSK | Save
  • HuM195 and its single-chain variable fragment increase Aβ phagocytosis in microglia via elimination of CD33 inhibitory signaling
    Journal Article

    Wong, E.; Malviya, M.; Jain, T.; Liao, G. P.; Kehs, Z.; Chang, J. C.; Studer, L.; Scheinberg, D. A.; Li, Y. M.
    Molecular Psychiatry (2024)

    Fulltext@MSK | Save
  • Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
    Research Letter

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Pak, T.; Chang, T.; Dao, P.; Moskowitz, A. J.; Stuver, R. N.; Ghione, P.; Galasso, N.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Cracking the chaperone code through the computational microscope
    Review

    Guarra, F.; Sciva, C.; Bonollo, G.; Pasala, C.; Chiosis, G.; Moroni, E.; Colombo, G.
    Cell Stress & Chaperones (2024)

    Fulltext@MSK | Save
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9
    Meeting Abstract

    Sborov, D. W.; Pawlyn, C.; Ishida, T.; Huang, J. S. Y.; Benjamin, R.; Iida, S.; Popat, R.; Kuroda, J.; Pianko, M. J.; Ramakrishnan, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup
    Meeting Abstract

    Cohen, A. D.; Voorhees, P. M.; Martin, T. G.; Lesokhin, A. M.; Hillengass, J.; Kaufman, J. L.; Schecter, J. M.; De Braganca, K. C.; Varsos, H.; Corsale, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Lesokhin, A. M.; Raza, M. S.; Acosta, J.; Muller, P.; O'Connell, A.; Yver, A.; Lou, C.; Finn, G.; Service, M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors
    Meeting Abstract

    Yi, J. S.; Czaplinski, J.; Bhushan, K.; Forrest, S. J.; Shukla, N.; Mack, S. C.; Hong, A. L.; Kentsis, A.; Stinehart, M.; Ezrre, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save